- Home
- OUST vs PHAT Comparison
OUST vs PHAT Comparison
Compare OUST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OUST | PHAT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 894.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OUST | PHAT |
|---|---|---|
| Price | $21.47 | $10.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $34.80 | $19.50 |
| AVG Volume (30 Days) | ★ 1.7M | 967.8K |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $20.76 | $91.62 |
| Revenue Next Year | $38.38 | $59.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $6.34 | $2.21 |
| 52 Week High | $41.65 | $18.31 |
Technical Indicators
Market Signals| Indicator | OUST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 51.33 | 35.03 |
| Support Level | $21.03 | $7.82 |
| Resistance Level | $31.52 | $12.77 |
| Average True Range (ATR) | 1.68 | 0.80 |
| MACD | 0.44 | -0.03 |
| Stochastic Oscillator | 51.68 | 7.28 |
Price Performance
Historical ComparisonAbout OUST Ouster Inc.
Ouster Inc is a provider of lidar sensors for the automotive, industrial, robotics, and smart infrastructure industries. Ouster's products include high-resolution scanning and solid-state digital lidar sensors, Velodyne Lidar sensors, and software solutions. The company operates in the Americas, Asia and Pacific, Europe, Middle East, and Africa regions. It derives maximum revenue from Americas.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.